Rate of Removal from the Circulation of Red Cells Sensitized with Different Amounts of Antibody

A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcγRIIA and FcγIIIA genes

“…[23][24][25][26][27][28][29][30][31][32][33][34] Rh prophylaxis is thought to be successful due to the efficient clearance of RhD-positive RBCs from the circulation and phagocytosis of anti-RhD-coated RBCs by macrophages in the spleen. 35 Accelerated clearance of coated RBCs and a relation between the rate of clearance and the degree of coating were observed many years ago. 36 Results from a decreasing dose response trial indicated that a dose of 100 g polyclonal anti-RhD was an adequate lower limit.…”

Effects of Corticosteroids and Splenectomy on the Immune Clearance and Destruction of Erythrocytes

“…The sites of sequestration in the case of IgG-coated cells are dependent on the number of antibody molecules coating the cell. At lower numbers of antibody molecules, splenic sequestration predominates while at higher numbers hepatic sequestration is most evident (8,14,15). Another important difference is that the guinea pig, unlike the rat, resembles man in being able to maintain body weight, spleen size, and albumin and globulin levels while being treated with as much as 50 mg/kg of cortisone acetate (12 The effectiveness of corticosteroids in preventing hepatic sequestration of IgM-sensitized cells is somewhat surprising since in most patients this therapy has been disappointing (1,2,17).…”

Antibody-Mediated Immune Suppression of Erythrocyte Alloimmunization Can Occur Independently from Red Cell Clearance or Epitope Masking in a Murine Model

“…As a result, a mAb capable of mimicking the effects of anti-D is highly desirable (12,26,27). There have been many attempts to make monoclonal anti-D Abs, and extreme efforts have gone into choosing those Abs that give the highest rates of RBC clearance for use in clinical studies (11,(28)(29)(30). In fact, regulators consider that for the prevention of HDFN a mAb specific for the RhD Ag should be demonstrated to cause RBC clearance before exposing pregnant women to the product.…”